A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer
Carey K. Anders(Duke University), Kimberly Blackwell(Duke University), Heather Shaw, Renee Welch(Duke University), Lin Gu(Cancer Research And Biostatistics), Monica Antenos(Northwestern University), Gretchen Kimmick(Johns Hopkins University), P. Kelly Marcom(Duke University), Sue Unruhe(Duke University), Stacey A. Snyder(Duke University), Bercedis L. Peterson(Duke University), P. Lyons(Duke University), Teresa K. Woodruff(Michigan State University)
Cited by 113
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917